[Preprint] Efficacy and safety of CoronaVac in healthcare professionals in Brazil
12 Apr, 2021 | 01:17h | UTC
Commentary on Twitter (thread – click for more)
Preprint on Brazilian trial by @butantanoficial of Sinovac's CoronaVac, 2 weeks apart. Data for 9,823 people who had 2 doses, 12,396 after 1 dose.The P1 ("Brazilian") variant of concern was not circulating in the areas the trial ran…1/n https://t.co/eN8ww8rYZF HT @josegallucci pic.twitter.com/hSR3QmZ0u8
— Hilda Bastian, PhD (@hildabast) April 11, 2021